CA
NZ
UK
AU
IND
US
Shares of WORK Medical Technology Group LTD (NASDAQ:WOK) closed at $2.04 on Friday, 24 July 2026, a gain of 8.51% on the session, based on price history compiled by StockAnalysis. That move lines up with the roughly +9% reading shown on undated gainer screens, …
Shares of YD Bio Limited (NASDAQ:YDES) drew attention on Friday, 25 July 2026, appearing among the day's percentage gainers with a move of roughly 10%. A market-data write-up published that day pegged the advance at about 9.8%, and the stock has been unusually active …
A ticker that appeared near the top of a US gainers screen this week, showing a move of roughly 53% on an unconfirmed figure, belongs to one of the market's freshest listings. The company is Instinct Bio Technical Company Holdings Inc. (NASDAQ:BIOT), which began …
On 17 June 2026, uniQure (NASDAQ:QURE) N.V. told investors the U.S. Food and Drug Administration had accepted three-year data from a small early-stage trial as the primary basis for a licence application for AMT-130, its one-time gene therapy for Huntington's disease. The shares closed …
Vertex (NASDAQ:VRTX) agreed on 6 July 2026 to buy Crinetics Pharmaceuticals for US$85 a share in cash, an equity value of roughly US$10 billion and by far the largest acquisition in its history. The deal buys an approved acromegaly pill and a late-stage adrenal …
Liquidia (NASDAQ:LQDA) reported $129.9 million of Yutrepia net product sales and a third consecutive profitable quarter on 11 May 2026, roughly eleven months after launch. The shares have risen about 386% over the past year, but a Delaware judge has yet to rule in …
Scribe Therapeutics (NASDAQ:SCTX) priced an upsized $128.7 million initial public offering at $15 a share and closed its first Nasdaq session at $21.65, a 44% gain that was nonetheless well below where the stock opened. The company is the first gene-editing developer to list …
TG Therapeutics (NASDAQ:TGTX) has raised its 2026 Briumvi revenue guidance twice this year, posted back-to-back profitable quarters and delivered positive readouts on a single-infusion starter regimen and a subcutaneous formulation. The shares have roughly doubled since December, but the company still sells one drug …
Incyte (NASDAQ:INCY) completed its $1.25 billion cash acquisition of Vega Therapeutics on 6 July 2026, adding a Phase 3 antibody for von Willebrand disease, then published multidose data a week later showing a median 81% cut in bleeding rates. With second-quarter results due 28 …
Legend Biotech (NASDAQ:LEGN)'s experimental in vivo CAR-T therapy LB2501 produced responses in every patient treated at the higher of two doses in a 12-patient Phase 1 study, and the shares jumped roughly a third on the news in June. Seven weeks later the stock …
Please wait processing your request...